Open AccessClinical significance and prospects of using ST2 in isсhemic heart failure patients
Author(s) -
Е. В. Гракова,
K. V. Kopeva,
А. Т. Тепляков,
А. В. Сваровская,
Michael Soldatenko,
О. Н. Огуркова,
Olesya E. Astafurova,
А. А. Гарганеева
Publication year - 2020
Publication title -
sibirskij medicinskij žurnal
Language(s) - English
Resource type - Journals
ISSN - 2073-8552
DOI - 10.29001/2073-8552-2020-35-2-89-97
Subject(s) - medicine , heart failure , biomarker , cardiology , adverse effect , clinical significance , gastroenterology , biochemistry , chemistry
Objective : The objective of this study is to assess the role of soluble ST2 (sST2) in developing adverse cardiovascular events (ACE) and fatal outcomes in patients with chronic heart failure (HF) during 18 [12.5; 35.5]-month follow-up period. Results . Depending on the median of baseline sST2 levels, all patients were retrospectively divided into two groups: group 1 enrolled patients with sST2 levels < 31.5 ng/mL (n = 22); and group 2 comprised patients with sST2 levels ≥ 31.5 ng/mL (n = 26). In group 1, the sST2 levels were 27.27 [23.94; 29.23] ng/mL, which was 33.9% higher (p < 0.1) than in group 2 (41.28 [34.86; 50.17] ng/mL). ACEs were registered in 9 cases (40.9%) in group 1 and in 17 cases (65.4%) in group 2 (p = 0.025). Based on ROC-analysis, baseline ST2 levels ≥ 33.53 ng/mL were considered a biomarker to predict an unfavorable course of ischemic heart failure during 18 [12.5; 35.5] months of follow-up period with sensitivity of 78.9% and specificity of 62.2% (AUC 0.719; 95% CI 0.562–0.845; p = 0.0059). Conclusion . The baseline sST2 levels may be considered a non-invasive biomarker allowing to predict the development of adverse cardiovascular events (ACE) and fatal outcomes in patients with chronic heart failure (HF) during 18 [12.5; 35.5] months of follow-up in addition to traditional risk factors.